Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

550 results

Medicine European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Referrals Remove Referrals filter Withdrawn applications Remove Withdrawn applications filter

Medicine type Accelerated assessment Remove Accelerated assessment filter Orphan medicine Remove Orphan medicine filter Additional monitoring Remove Additional monitoring filter Conditional approval Remove Conditional approval filter

Categories Human Remove Human filter Veterinary Remove Veterinary filter

Sort by

List item

Human medicine European public assessment report (EPAR): Hemlibra (updated)

Emicizumab, Hemophilia A
Date of authorisation: 23/02/2018, , Revision: 13, Authorised, Last updated: 06/03/2023
List item

Human medicine European public assessment report (EPAR): Veyvondi (updated)

vonicog alfa, von Willebrand Diseases
Date of authorisation: 31/08/2018, , Revision: 6, Authorised, Last updated: 06/03/2023
List item

Human medicine European public assessment report (EPAR): Empliciti (updated)

Elotuzumab, Multiple Myeloma
Date of authorisation: 11/05/2016, , Revision: 11, Authorised, Last updated: 06/03/2023
List item

Human medicine European public assessment report (EPAR): Calquence (updated)

Acalabrutinib, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 05/11/2020, , Revision: 4, Authorised, Last updated: 06/03/2023
List item

Human medicine European public assessment report (EPAR): Mysimba (updated)

bupropion hydrochloride, naltrexone hydrochloride, Obesity; Overweight
Date of authorisation: 26/03/2015, , Revision: 24, Authorised, Last updated: 03/03/2023
List item

Human medicine European public assessment report (EPAR): Aimovig (updated)

erenumab, Migraine Disorders
Date of authorisation: 26/07/2018, , Revision: 9, Authorised, Last updated: 02/03/2023
List item

Human medicine European public assessment report (EPAR): Revlimid (updated)

lenalidomide, Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes
Date of authorisation: 14/06/2007, , Revision: 49, Authorised, Last updated: 02/03/2023
List item

Human medicine European public assessment report (EPAR): Pemazyre (updated)

pemigatinib, Cholangiocarcinoma
Date of authorisation: 26/03/2021, , , , Revision: 5, Authorised, Last updated: 02/03/2023
List item

Human medicine European public assessment report (EPAR): Imjudo (updated)

Tremelimumab, Carcinoma, Hepatocellular
Date of authorisation: 15/12/2022, , Authorised, Last updated: 02/03/2023
List item

Human medicine European public assessment report (EPAR): Scemblix (updated)

asciminib hydrochloride, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Date of authorisation: 25/08/2022, , , Revision: 2, Authorised, Last updated: 02/03/2023
List item

Human medicine European public assessment report (EPAR): Maviret (updated)

glecaprevir, pibrentasvir, Hepatitis C, Chronic
Date of authorisation: 26/07/2017, , Revision: 21, Authorised, Last updated: 02/03/2023
List item

Human medicine European public assessment report (EPAR): Vyndaqel (updated)

tafamidis, Amyloidosis
Date of authorisation: 16/11/2011, , , , Revision: 25, Authorised, Last updated: 02/03/2023
List item

Human medicine European public assessment report (EPAR): MenQuadfi (updated)

Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid, Meningitis, Meningococcal
Date of authorisation: 18/11/2020, , Revision: 8, Authorised, Last updated: 01/03/2023
List item

Human medicine European public assessment report (EPAR): Spravato (updated)

esketamine hydrochloride, Depressive Disorder
Date of authorisation: 18/12/2019, , Revision: 7, Authorised, Last updated: 01/03/2023
List item

Human medicine European public assessment report (EPAR): Revestive (updated)

teduglutide, Malabsorption Syndromes
Date of authorisation: 30/08/2012, , , Revision: 21, Authorised, Last updated: 01/03/2023
List item

Human medicine European public assessment report (EPAR): Cibinqo (updated)

Abrocitinib, Dermatitis, Atopic
Date of authorisation: 09/12/2021, , , Revision: 3, Authorised, Last updated: 28/02/2023
List item

Human medicine European public assessment report (EPAR): Lenvima (updated)

lenvatinib mesilate, Thyroid Neoplasms
Date of authorisation: 28/05/2015, , , Revision: 17, Authorised, Last updated: 28/02/2023
List item

Human medicine European public assessment report (EPAR): Onpattro (updated)

patisiran sodium, Amyloidosis, Familial
Date of authorisation: 27/08/2018, , , , Revision: 10, Authorised, Last updated: 28/02/2023
List item

Human medicine European public assessment report (EPAR): Hemgenix (updated)

etranacogene dezaparvovec, Hemophilia B
Date of authorisation: 20/02/2023, , , , Authorised, Last updated: 28/02/2023
List item

Human medicine European public assessment report (EPAR): Tukysa (updated)

Tucatinib, Breast Neoplasms; Neoplasm Metastasis
Date of authorisation: 11/02/2021, , Revision: 3, Authorised, Last updated: 27/02/2023
List item

Human medicine European public assessment report (EPAR): Veltassa

patiromer sorbitex calcium, Hyperkalemia
Date of authorisation: 19/07/2017, , Revision: 7, Authorised, Last updated: 24/02/2023
List item

Human medicine European public assessment report (EPAR): Pelmeg

pegfilgrastim, Neutropenia
Date of authorisation: 20/11/2018, , , Revision: 7, Authorised, Last updated: 24/02/2023
List item

Human medicine European public assessment report (EPAR): Cegfila (previously Pegfilgrastim Mundipharma)

pegfilgrastim, Neutropenia
Date of authorisation: 19/12/2019, , , Revision: 7, Authorised, Last updated: 24/02/2023
List item

Human medicine European public assessment report (EPAR): Dovprela (previously Pretomanid FGK)

Pretomanid, Tuberculosis, Multidrug-Resistant
Date of authorisation: 31/07/2020, , , , Revision: 7, Authorised, Last updated: 24/02/2023
List item

Human medicine European public assessment report (EPAR): Evenity

Romosozumab, Osteoporosis
Date of authorisation: 09/12/2019, , Revision: 3, Authorised, Last updated: 23/02/2023